A multilevel approach for screening natural compounds as an antiviral agent for COVID-19

Comput Biol Chem. 2022 Jun:98:107694. doi: 10.1016/j.compbiolchem.2022.107694. Epub 2022 May 11.

Abstract

The COVID-19 has a worldwide spread, which has prompted concerted efforts to find successful drug treatments. Drug design focused on finding antiviral therapeutic agents from plant-derived compounds which may disrupt the attachment of SARS-CoV-2 to host cells is with a pivotal need and role in the last year. Herein, we provide an approach based on drug design methods combined with machine learning approaches to classify and discover inhibitors for COVID-19 from natural products. The spike receptor-binding domain (RBD) was docked with database of 125 ligands. The docking protocol based on several steps was performed within Autodock Vina to identify the high-affinity binding mode and to reveal more insights into interaction between the phytochemicals and the RBD domain. A protein-ligand interaction analyzer has been developed. The drug-likeness properties of explored inhibitors are analyzed in the frame of exploratory data analyses. The developed computational protocol yielded a comprehensive pipeline for predicting the inhibitors to prevent the entry RBD region.

Keywords: Cluster analyses; Computer-aided drug design; DFT; Docking; Principal component analysis.

MeSH terms

  • Antiviral Agents* / chemistry
  • Antiviral Agents* / pharmacology
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • COVID-19 Drug Treatment*
  • Drug Evaluation, Preclinical
  • Humans
  • Ligands
  • Molecular Docking Simulation
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / metabolism

Substances

  • Antiviral Agents
  • Biological Products
  • Ligands
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2